Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Etoposide 6Radiotherapy 4Cisplatin 3Docetaxel 2Carboplatin 2venetoclax 1trametinib 1toripalimab 1tislelizumab 1talazoparib 1sacituzumab govitecan 1rovalpituzumab tesirine 1regorafenib 1poly ICLC 1pembrolizumab 1olaparib 1obatoclax 1nintedanib 1fludarabine phosphate 1etoposide phosphate 1enoxaparin sodium 1durvalumab 1alpha-Tocopherol 1Vitamin E 1Topotecan 1Tomography, Optical Coherence 1Thymalfasin 1Taxes 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Small Cell Lung Carcinoma × obatoclax × Clear all
NCT01563601 2012-08-15

Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡